Bremer, Sebastian Christopher Benjamin

[["dc.bibliographiccitation.firstpage","2828"],["dc.bibliographiccitation.issue","12"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Bremer, Sebastian C. B.; 1Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; alexander.koenig@med.uni-goettingen.de (A.O.K.); ahmad.amanzada@med.uni-goettingen.de (A.A.); volker.ellenrieder@med.uni-goettingen.de (V.E.)"],["dc.contributor.affiliation","Bittner, Gabi; 2Institute of Pathology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; bittnergabi@outlook.de (G.B.); omar.elakad@med.uni-goettingen.de (O.E.); dinterhelen@gmail.com (H.D.); philipp.stroebel@med.uni-goettingen.de (P.S.); hanibal.bohnenberger@med.uni-goettingen.de (H.B.)"],["dc.contributor.affiliation","Elakad, Omar; 2Institute of Pathology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; bittnergabi@outlook.de (G.B.); omar.elakad@med.uni-goettingen.de (O.E.); dinterhelen@gmail.com (H.D.); philipp.stroebel@med.uni-goettingen.de (P.S.); hanibal.bohnenberger@med.uni-goettingen.de (H.B.)"],["dc.contributor.affiliation","Dinter, Helen; 2Institute of Pathology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; bittnergabi@outlook.de (G.B.); omar.elakad@med.uni-goettingen.de (O.E.); dinterhelen@gmail.com (H.D.); philipp.stroebel@med.uni-goettingen.de (P.S.); hanibal.bohnenberger@med.uni-goettingen.de (H.B.)"],["dc.contributor.affiliation","Gaedcke, Jochen; 3Clinic for General, Visceral and Pediatric Surgery, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; jochen.gaedcke@med.uni-goettingen.de"],["dc.contributor.affiliation","König, Alexander O.; 1Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; alexander.koenig@med.uni-goettingen.de (A.O.K.); ahmad.amanzada@med.uni-goettingen.de (A.A.); volker.ellenrieder@med.uni-goettingen.de (V.E.)"],["dc.contributor.affiliation","Amanzada, Ahmad; 1Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; alexander.koenig@med.uni-goettingen.de (A.O.K.); ahmad.amanzada@med.uni-goettingen.de (A.A.); volker.ellenrieder@med.uni-goettingen.de (V.E.)"],["dc.contributor.affiliation","Ellenrieder, Volker; 1Clinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; alexander.koenig@med.uni-goettingen.de (A.O.K.); ahmad.amanzada@med.uni-goettingen.de (A.A.); volker.ellenrieder@med.uni-goettingen.de (V.E.)"],["dc.contributor.affiliation","Freiherr von Hammerstein-Equord, Alexander; 4Clinic for Cardiac, Thoracic and Vascular Surgery, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; alexander.hammerstein@med.uni-goettingen.de"],["dc.contributor.affiliation","Ströbel, Philipp; 2Institute of Pathology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; bittnergabi@outlook.de (G.B.); omar.elakad@med.uni-goettingen.de (O.E.); dinterhelen@gmail.com (H.D.); philipp.stroebel@med.uni-goettingen.de (P.S.); hanibal.bohnenberger@med.uni-goettingen.de (H.B.)"],["dc.contributor.affiliation","Bohnenberger, Hanibal; 2Institute of Pathology, University Medical Center Goettingen, Georg-August-University, 37075 Goettingen, Germany; bittnergabi@outlook.de (G.B.); omar.elakad@med.uni-goettingen.de (O.E.); dinterhelen@gmail.com (H.D.); philipp.stroebel@med.uni-goettingen.de (P.S.); hanibal.bohnenberger@med.uni-goettingen.de (H.B.)"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Bittner, Gabi"],["dc.contributor.author","Elakad, Omar"],["dc.contributor.author","Dinter, Helen"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","König, Alexander O."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Freiherr von Hammerstein-Equord, Alexander"],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Bohnenberger, Hanibal"],["dc.date.accessioned","2022-07-01T07:35:31Z"],["dc.date.available","2022-07-01T07:35:31Z"],["dc.date.issued","2022"],["dc.date.updated","2022-07-08T10:03:36Z"],["dc.description.abstract","Tumor grading is a robust prognostic predictor in patients with neuroendocrine neoplasms (NEN) and guides therapy, especially in tumors with high proliferation. NEN can be separated into well-differentiated and poorly differentiated types. The more aggressive NEN have been further separated into neuroendocrine tumors (NET G3) with a better prognosis and neuroendocrine carcinomas (NEC) with a worse prognosis. Despite this distinction’s tremendous clinical and therapeutic relevance, optimal diagnostic biomarkers are still lacking. In this study, we analyzed the protein expression and prognostic impact of Enhancer of Zeste Homolog 2 (EZH2) by immunohistochemistry in 219 tissue samples of gastroenteropancreatic (GEP-NEN) and pulmonary NEN (P-NEN). EZH2 was almost exclusively expressed in NEN with a proliferation rate above 20% (G3), while all low-grade tumors were nearly negative. Among high-grade NEN, 65% showed high and 35% low expression of EZH2. In this group, the high expression of EZH2 was significantly associated with poor overall survival and NEC histology. Interestingly, EZH2 seems to act independently of Polycomb Repressive Complex 2 (PRC2) in NEN. In conclusion, we propose EZH2 as a robust biomarker for distinguishing between NET G3 and NEC among gastroenteropancreatic and pulmonary NEN."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.description.sponsorship","University Medical Center Göttingen"],["dc.description.sponsorship","Else-Kröner-Fresenius-Stiftung"],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3390/cancers14122828"],["dc.identifier.pii","cancers14122828"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112190"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112412"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-581"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","342"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Scandinavian Journal of Gastroenterology"],["dc.bibliographiccitation.lastpage","349"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Tsaknakis, Birgit"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","G. Goetze, Robert"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2020-12-10T18:14:44Z"],["dc.date.available","2020-12-10T18:14:44Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1080/00365521.2019.1585571"],["dc.identifier.eissn","1502-7708"],["dc.identifier.issn","0036-5521"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/74599"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Evaluation of liver stiffness by 2D-SWE in combination with non-invasive parameters as predictors for esophageal varices in patients with advanced chronic liver disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Eiffert, Helmut"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Bremer, S. C. B."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, A."],["dc.date.accessioned","2018-11-07T10:23:13Z"],["dc.date.available","2018-11-07T10:23:13Z"],["dc.date.issued","2017"],["dc.format.extent","626"],["dc.identifier.doi","10.1007/s00108-017-0228-x"],["dc.identifier.isi","000402791100013"],["dc.identifier.pmid","28389763"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42417"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","Spontaneous Remission of HCV Infection after autologous Stem Cell Transplantation in a 58-year-old Man (vol 58, pg 626, 2017)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","367"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Ultrasound"],["dc.bibliographiccitation.lastpage","374"],["dc.bibliographiccitation.volume","50"],["dc.contributor.affiliation","Bremer, Sebastian C. B.; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Knoop, Richard F.; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Porsche, Melissa; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Amanzada, Ahmad; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Ellenrieder, Volker; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Neesse, Albrecht; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.affiliation","Kunsch, Steffen; 1\r\nClinic for Gastroenterology, Gastrointestinal Oncology and Endocrinology\r\nUniversity Medical Center Goettingen, Georg‐August‐University\r\nGoettingen Germany"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Porsche, Melissa"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Petzold, Golo"],["dc.date.accessioned","2021-12-01T09:23:12Z"],["dc.date.available","2021-12-01T09:23:12Z"],["dc.date.issued","2021"],["dc.date.updated","2022-06-14T22:49:32Z"],["dc.description.abstract","Abstract Purpose Increased gallbladder wall thickness (GBWT) is a common finding. Reported causes include advanced chronic liver disease (ACLD), ascites and hypalbuminemia. GBWT is a marker for the prediction of esophageal varices. It remains unclear which of these factors is the decisive driver of GBWT. We aim to investigate whether there is a predominant factor associated with the GBWT. Methods We enrolled 258 patients with ascites, hypalbuminemia and/or ACLD and 98 healthy volunteers that underwent abdominal ultrasound. Differences of mean GBWT in subgroups of patients with ACLD, ascites, and/or hypalbuminemia were analyzed. Correlation between various parameters and GBWT were calculated using multiple regression analysis. Results GBWT in patients with ACLD + ascites + hypalbuminemia (n = 59; 5.70 ± 2.05 mm) was pathologically increased compared to patients with hypalbuminemia + ascites without ACLD (n = 36; 2.14 ± 0.66 mm; p < .001) and to patients with only hypalbuminemia (n = 76; 2.02 ± 0.80 mm; p < .001). GBWT of patients with ACLD + hypalbuminemia (n = 30; 3.42 ± 1.52 mm) and with ACLD and normal albumin level were not different (n = 46; 3.10 ± 1.62 mm; p > .999). Significant correlation was seen between GBWT and ACLD (r = .53; p < .001) and ascites (r = .51; p < .001) but not albumin level (r = .04; p = .510). Conclusion We demonstrate that ACLD is predominantly associated with GBWT. In contrast to the current literature, serum albumin level appears not to be associated with pathological GBWT."],["dc.description.abstract","Representative image of a gallbladder of a patient with liver cirrhosis and ascites using a convex transducer (4.0 MHz). The gallbladder wall is pathologically thickened image"],["dc.identifier.doi","10.1002/jcu.23077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94586"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.publisher","John Wiley & Sons, Inc."],["dc.relation.eissn","1097-0096"],["dc.relation.issn","0091-2751"],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited."],["dc.title","Pathological gallbladder wall thickening is associated with advanced chronic liver disease and independent of serum albumin"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Surgical Endoscopy"],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Wedi, Edris"],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2021-04-14T08:24:44Z"],["dc.date.available","2021-04-14T08:24:44Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00464-020-07808-w"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81403"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.relation.eissn","1432-2218"],["dc.relation.issn","0930-2794"],["dc.title","Endoscopic submucosal dissection with an additional working channel (ESD+): a novel technique to improve procedure time and safety of ESD"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","621"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Der Internist"],["dc.bibliographiccitation.lastpage","625"],["dc.bibliographiccitation.volume","58"],["dc.contributor.author","Reinhardt, Lars"],["dc.contributor.author","Eiffert, Helmut"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Stroebel, Philipp"],["dc.contributor.author","Bremer, S. C. B."],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, A."],["dc.date.accessioned","2018-11-07T10:23:13Z"],["dc.date.available","2018-11-07T10:23:13Z"],["dc.date.issued","2017"],["dc.description.abstract","We report about a 58-year-old man with a chronic and treatment-naive hepatitis C virus (HCV) infection of genotype 1b, who had undergone autologous stem cell transplantation twice due to multiple myeloma. Subsequently, a high-level viremic reactivation of an occult hepatitis B virus (HBV) infection and also a reverse seroconversion was observed. Furthermore, a sustained spontaneous remission of HCV infection was seen. Antiviral therapy of HBV infection was initiated with tenofovir. Seven months after therapy initiation, the patient acquired an \"anti-HBc-only\" status. Antiviral therapy with tenofovir is still continued. The patient is in a good clinical condition."],["dc.identifier.doi","10.1007/s00108-017-0206-3"],["dc.identifier.isi","000402791100012"],["dc.identifier.pmid","28235985"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/42415"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.issn","1432-1289"],["dc.relation.issn","0020-9554"],["dc.title","Spontaneous remission of HCV infection after autologous stem cell transplantation in a 58-year-old man"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e000258"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open Gastroenterology"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Mavropoulou, Eirini"],["dc.contributor.author","Ternes, Kristin"],["dc.contributor.author","Mechie, Nicolae-Catalin"],["dc.contributor.author","Bremer, Sebastian Christopher Benjamin"],["dc.contributor.author","Kunsch, Steffen"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Amanzada, Ahmad"],["dc.date.accessioned","2019-07-09T11:50:10Z"],["dc.date.available","2019-07-09T11:50:10Z"],["dc.date.issued","2019"],["dc.description.abstract","Background Concurrent cytomegalovirus (CMV) colitis in inflammatory bowel disease (IBD) and after haematopoietic stem cell transplantation (HSCT) is an important clinical entity associated with high rates of morbidity and mortality. Methods A retrospective study of 47 patients with IBD and 61 HSCT patients was performed regarding the evaluation of diagnostic accuracy of applied methods, predictors, risk factors for CMV disease manifestation, the proportion of patients with antiviral treatment and disease outcome. Results The sensitivity of quantitative PCR (qPCR) with a cut-off value of >250 copies/mg for CMV colitis in patients with IBD and HSCT patients was 79% and 92%, respectively. Predictors for CMV colitis in the IBD cohort were anaemia and the presence of endoscopic ulcers. Glucocorticoids, calcineurin inhibitors and >2 concurrent lines of treatment with immunosuppressive drugs could be identified as risk factors for CMV colitis in the IBD cohort with an OR of 7.1 (95% CI 1.7 to 29.9), 21.3 (95% CI 2.4 to 188.7) and 13.4 (95% CI 3.2 to 56.1), respectively. Predictors and risk factors for CMV gastroenteritis in the HSCT cohort was the presence of endoscopic ulcers (OR 18.6, 95% CI 3.3 to 103.7) and >2 concurrent lines of treatment with immunosuppressive drugs. Antiviral therapy was administered in 70% of patients with IBD and 77% of HSCT patients with CMV disease. 71% of antiviraltreated patients with IBD showed an improvement of their disease activity and 14% underwent colectomy. The mortality rate of HSCT patients was 21% irrespective of their CMV status. Conclusions In addition to the implementation of histological methods, qPCR may be performed in patients with suspected high-risk IBD and HSCT patients for CMV colitis. Independent validations of these results in further prospective studies are needed."],["dc.identifier.doi","10.1136/bmjgast-2018-000258"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15876"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59717"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Cytomegalovirus colitis in inflammatory bowel disease and after haematopoietic stem cell transplantation: diagnostic accuracy, predictors, risk factors and disease outcome"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1"],["dc.bibliographiccitation.journal","BioMed Research International"],["dc.bibliographiccitation.lastpage","6"],["dc.bibliographiccitation.volume","2022"],["dc.contributor.author","Knoop, Richard F."],["dc.contributor.author","Gaertner, Pauline C."],["dc.contributor.author","Petzold, Golo"],["dc.contributor.author","Amanzada, Ahmad"],["dc.contributor.author","Ellenrieder, Volker"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Bremer, Sebastian C. B."],["dc.contributor.author","Kunsch, Steffen"],["dc.date.accessioned","2022-06-01T09:39:38Z"],["dc.date.available","2022-06-01T09:39:38Z"],["dc.date.issued","2022"],["dc.description.abstract","Background and Aims. In contrast to guideline recommendations, endoscopic testing for Helicobacter pylori is frequently performed under Helicobacter pylori suppressive conditions, e.g., intake of proton-pump inhibitors (PPI), preceded antibiotic treatment, or recent gastrointestinal bleeding. Our study\\’s aim was to retest patients with—under suppressive conditions—negative test results. This was carried out in order to examine the rate of false negative tests previously gathered under suppressive conditions. Methods. The trial was conducted in a large patient collective in a university hospital. Every elective esophagogastroduodenoscopy from in- and outpatients was included. Prior to endoscopy, suppressive conditions were collected via standardized questionnaire. If Helicobacter pylori testing was indicated, both helicobacter urease test and histology were performed in analogy to the Sydney classification. In case of a negative result under suppressive conditions, the patient was reinvited after, if possible, withdrawal of suppressive condition in order to perform a urea breath test (UBT). Results. 1,216 patients were included (median 59 years, 72.0% inpatients, 28.0% outpatients). Overall, 60.6% (737) were under Helicobacter pylori suppressive conditions. The main suppressive condition was intake of PPIs (54.5%). In 53.7% (653) of all included cases, Helicobacter pylori testing was performed. Of those, 14.1% (92) had a positive test, and 85.9% (561) were negative. Out of the patients with negative result, 50.8% (285) were tested under suppressive conditions and consequently invited for retesting via UBT. In 20.4% (45), suppressive conditions could not be ceased. In 22.8% (65), retesting was conducted. Of those, 98.5% (64) congruently presented a negative result again, and only 1.5% (1) was positive for Helicobacter pylori. Conclusion. Many patients undergoing esophagogastroduodenoscopy in everyday clinical practice are tested for Helicobacter pylori under suppressive conditions leading to a potentially higher risk of false negative results. However, our research shows that this issue might be overestimated."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.1155/2022/5380001"],["dc.identifier.pii","5380001"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/108523"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-572"],["dc.relation.eissn","2314-6141"],["dc.relation.issn","2314-6133"],["dc.rights","CC BY 4.0"],["dc.title","Systematic Retesting for Helicobacter pylori: The Potential Overestimation of Suppressive Conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]